Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.
Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥8 (p = 0.004), an extent of disease value (EOD) of ≥2 (p = 0.004), and a 3-month PSA level >1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. For OS, a 3-month PSA level >1% of the pretreatment level was an independent predictor of time to CRPC (p = 0.004).
Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level >1% of the pretreatment level correlated with poor a prognosis.
Figure 1
This is a list of supplementary files associated with this preprint. Click to download.
Kaplan-Meier curve showing the time to CRPC (median: 15 months).
Kaplan-Meier curve showing the overall survival (median: 92 months).
Comparison of Kaplan-Meier curves between the PSA ≥1% group and the PSA <1% group. The PSA ≥1% group shows a significantly shorter time to CRPC than the PSA <1% group (p = 0.0027).
Univariate analysis of potential baseline covariates with the time to CRPC.
Loading...
Posted 18 Mar, 2021
On 27 Mar, 2021
Invitations sent on 26 Feb, 2021
On 18 Feb, 2021
On 18 Feb, 2021
On 18 Feb, 2021
On 11 Jan, 2021
Posted 18 Mar, 2021
On 27 Mar, 2021
Invitations sent on 26 Feb, 2021
On 18 Feb, 2021
On 18 Feb, 2021
On 18 Feb, 2021
On 11 Jan, 2021
Objective: To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels after androgen deprivation therapy (ADT) on castration-resistant prostate cancer (CRPC) progression and overall survival (OS) in mHSPC patients.
Results: In 71 primary mHSPC patients treated with ADT, the median times to CRPC and OS were 15 months and 92 months, respectively. In multivariate analysis, a Gleason score of ≥8 (p = 0.004), an extent of disease value (EOD) of ≥2 (p = 0.004), and a 3-month PSA level >1% of the pretreatment level (p = 0.017) were independent predictors of shorter time to CRPC. The area under the receiver operating characteristic curve was feasible at 0.822. For OS, a 3-month PSA level >1% of the pretreatment level was an independent predictor of time to CRPC (p = 0.004).
Three factors were independent predictors of shorter time to CRPC. A 3-month PSA level >1% of the pretreatment level correlated with poor a prognosis.
Figure 1
Loading...